The highly anticipated Anthem Biosciences IPO has reached its crucial stage – the IPO allotment status is being finalized today, July 17, 2025. Following an overwhelming response from institutional, HNI, and retail investors, market participants are now eagerly waiting to see if they’ve secured allotment in one of the most awaited biotechnology IPOs of the year.
With a strong market buzz and healthy GMP premiums, all eyes are now on the allotment outcome and the listing day returns. This post provides a detailed view of the IPO allotment process, how to check your status, company insights, market sentiment, and what investors can expect post-allotment.
🏢 About Anthem Biosciences Ltd. – Company Overview
🔬 Anthem Biosciences is a Bengaluru-based Contract Research and Manufacturing Services (CRAMS) provider in the biotech and pharmaceutical sector. The company specializes in offering end-to-end solutions in preclinical R&D, scale-up services, APIs, intermediates, and formulations.
💼 With a diversified clientele base spanning global pharma giants and biotech firms, Anthem operates multiple state-of-the-art facilities and has earned a reputation for innovation-driven execution.
📈 Over the years, Anthem has shown impressive financial growth, a solid global presence, and a strong pipeline of research contracts that makes it an appealing player for long-term investors in India’s booming biotech space.
💸 IPO Details Recap
-
IPO Opened: July 14, 2025
-
Closed On: July 16, 2025
-
Price Band: ₹555 – ₹570
-
Issue Size: ₹1,500 crore (Fresh + OFS)
-
Lot Size: 26 shares
-
GMP (Grey Market Premium): ₹144 – ₹148 (as on July 17)
-
Listing Date: July 21, 2025 (Tentative)
📊 Subscription Figures:
-
Overall Subscription: ~64×
-
QIBs: 120×
-
HNIs: 96×
-
Retail: 18.2×
💥 This kind of oversubscription clearly indicates strong investor trust in the company’s fundamentals and long-term growth potential.
✅ How to Check Anthem Biosciences IPO Allotment Status
If you’ve applied for the IPO, here’s how you can check whether you’ve been allotted shares:
📍 Option 1: Kfin Technologies (Registrar Website)
-
Select “Anthem Biosciences Ltd” from the dropdown
-
Enter:
-
PAN OR
-
Application Number OR
-
DP Client ID
-
-
Complete CAPTCHA and click Submit
📍 Option 2: BSE India Portal
-
Select:
-
Issue Type: Equity
-
Issue Name: Anthem Biosciences
-
-
Enter your PAN, Application Number, and CAPTCHA
-
Click Search
📍 Option 3: NSE Website
-
Go to NSE IPO Bid Check
-
Choose the IPO option
-
Enter PAN and Application ID
-
Click Submit
📅 Important Dates You Should Know
-
🗓️ Allotment Finalization: July 17, 2025
-
🧾 Refunds Initiate: July 18, 2025
-
🧮 Demat Credit of Shares: July 18, 2025
-
💹 Stock Market Listing: July 21, 2025 (Monday)
🔎 Market Sentiment & GMP Trend
The Grey Market Premium (GMP) for Anthem Biosciences IPO is currently ranging around ₹144–₹148, indicating a potential listing price of ₹714–₹718, which translates to a ~25–30% premium over the upper price band of ₹570.
📌 This strong GMP reflects:
-
Investor confidence in the company’s scalable R&D model
-
Sectoral optimism in biotech & CRAMS services
-
Global investor participation
🧪 Given its innovation-driven model and global reach, analysts expect Anthem to draw long-term institutional attention post-listing too.
📊 Impact on Share Market
🔼 Bullish Sentiment: The overwhelming subscription and high GMP are likely to lift biotech sector stocks, especially peers in the CRAMS and pharma innovation spaces.
💹 Sector Re-Rating Possible: With Anthem’s successful listing, there could be a positive rerating of listed players like Syngene, Divi’s Labs, or Laurus Labs.
👨💼 Retail Investor Optimism: Given the retail portion was subscribed ~18×, and expected listing gains are 25–30%, this IPO may improve sentiment and retail activity across mid-cap IPOs.
📢 Nifty Pharma and SME indices could also see upward momentum depending on listing day action.
🧠 Retail Investors – What to Keep in Mind
✔️ If Allotted:
-
Track demat credit on July 18
-
Plan whether to hold for long-term biotech exposure or book listing gains
❌ If Not Allotted:
-
Watch listing closely
-
Evaluate post-listing buying opportunity if price stabilizes below GMP
🧭 Long-term investors may consider building a small position post-listing based on Q1 FY26 results and management commentary.
📉 Stock Market Disclaimer
Disclaimer: This post is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy/sell any stock or share. Investing in the stock market involves risk. Past performance is not indicative of future results. Always conduct your own research or consult a licensed financial advisor before making investment decisions.
